Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus HUMALOG PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus HUMALOG PEN.
HUMALOG MIX 50/50 PEN vs HUMALOG PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
None Documented
None Documented
Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance.
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination.
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Category C
Category C
Insulin Analog
Insulin Analog